[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440039":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":80,"centralContacts":84,"locations":89,"responsibleParty":108,"collaborators":110,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":37,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":37,"enrollmentInfo":123,"targetDuration":37,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":37,"overallStatus":92,"whyStopped":37,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Treatment Plan (Cohort One)","EXPERIMENTAL","Patients undergo SPECT\u002FCT with stress test and echocardiogram with strain before RT, 6-8 weeks and 12 months after completion of RT. Patients also participate in 6 MWT before RT, 2-3 and 6-7 weeks during RT, then 6-8 weeks, 4-6 months and 12 months after completion of RT. Patients undergo blood sample collection and complete questionnaires over 3-5 minutes before RT, 2-3, 4-5, 6-7 weeks after the initiation of RT, then at 3, 6, 12, and 24 months after completion of RT.",[13,14,15,16,17,18,19],"Procedure: 6 Minute Walk Functional Test","Procedure: Biospecimen Collection","Procedure: Computed Tomography","Procedure: Echocardiography","Procedure: Exercise Cardiac Stress Test","Other: Questionnaire Administration","Procedure: Single Photon Emission Computed Tomography",{"label":21,"type":10,"description":11,"interventionNames":22},"Model Based Personalized Treatment Plan (Cohort Two)",[13,14,15,16,17,18,19],[24,33,38,50,56,63,67],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"PROCEDURE","6 Minute Walk Functional Test","Participate in 6 MWT",[21,9],[30,31,32],"6MWT","SIX MINUTE WALK","SIXMW1",{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Biospecimen Collection","Undergo blood and urine sample collection",[21,9],null,{"type":25,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Computed Tomography","Undergo SPECT\u002FCT",[21,9],[43,44,45,46,47,48,49],"CAT","CAT Scan","Computerized Axial Tomography","Computerized Tomography","CT","CT Scan","tomography",{"type":25,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Echocardiography","Undergo echocardiogram",[21,9],[55],"ECHO_TEST",{"type":25,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"Exercise Cardiac Stress Test","Undergo stress test",[21,9],[61,62],"ECST","Exercise Stress Test",{"type":6,"name":64,"description":65,"armGroupLabels":66,"otherNames":37},"Questionnaire Administration","Complete questionnaires",[21,9],{"type":25,"name":68,"description":40,"armGroupLabels":69,"otherNames":70},"Single Photon Emission Computed Tomography",[21,9],[71,72,73,74,75,76,77,78,79],"Medical Imaging, Single Photon Emission Computed Tomography","Single Photon Emission Tomography","single-photon emission computed tomography","SPECT","SPECT imaging","SPECT SCAN","SPET","tomography, emission computed, single photon","Tomography, Emission-Computed, Single-Photon",[81],{"name":82,"affiliation":5,"role":83},"Zhongxing Liao, MD","PRINCIPAL_INVESTIGATOR",[85],{"name":82,"role":86,"phone":87,"phoneExt":37,"email":88},"CONTACT","832-829-5312","zliao@mdanderson.org",[90],{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":99,"coordinates":100},"Point",[101,102],-95.36327,29.76328,{"lat":102,"lon":101},[105,107],{"name":106,"role":86,"phone":87,"phoneExt":37,"email":88},"Zhongxing Liao",{"name":106,"role":83,"phone":37,"phoneExt":37,"email":37},{"type":109,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[111],{"name":112,"class":113},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100440039","cardiovascular-injury-and-cardiac-fitness-in-locally-advanced-non-small-cell-lung-cancer-patients-receiving-model-based-personalized-chemoradiation-100440039",false,"NCT05010109","Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation","Longitudinal Assessment of Cardiovascular Injury and Cardiac Fitness in LA-NSCLC Patients Receiving Model Based Personalized Chemoradiation - an Adaptive Cohort Registration Study","Inclusion Criteria:\n\n1. Patient with histologic diagnosis of non-small cell lung cancer, small cell lung cancer, or limited stage - small cell lung cancer (L-SCLC)\n2. The recommended treatment is thoracic radiation therapy combined with concurrent systemic therapy (chemotherapy and\u002For immunotherapy) with or without neoadjuvant and\u002For adjuvant systemic therapy (chemotherapy, immunotherapy, targeted therapy)\n3. \\>\u002F= 18 years of age\n4. KPS \\>\u002F= 70\n5. Willing and able to sign informed consents\n6. Willing to perform 6minute walking test\n7. Willing to preform required cardiac biomarker test for primary end point assessment.\n\nExclusion criteria:\n\n1. Unable or unwilling to give written informed consent\n2. Previous history of RT to the thorax overlapping with the current treatment field.\n3. Pregnant or breast-feeding\n4. Renal failure necessitating dialysis\n5. Unwilling to perform protocol tests\n6. Contraindication for any protocol tests","ALL","18 Years",{"count":124,"type":125},100,"ESTIMATED","INTERVENTIONAL",[128],"NA","This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving model based personalized chemoradiation. The goal of this study is to learn more about the risk of developing heart disease as a result of chemoradiation treatment for lung cancer. Researchers also want to learn if the risk can be reduced by using a patient's individual risk profile to guide cancer treatment and help protect the heart.",[131,132,133,134,135],"Locally Advanced Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","2026-03-09",{"date":138,"type":139},"2026-03-11","ACTUAL",{"date":141,"type":139},"2021-07-05",{"date":143,"type":125},"2027-02-02",{"name":5,"class":6},1]